Discover how genetic profiles and ancestry may influence the underlying neuropathology and diagnostic accuracy of ...

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adult hypercholesterolemia and HeFH.

The FDA has granted Fast Track designation to invobenitug, an investigational anti-cDPP3 monoclonal antibody designed to restore RAAS balance in cardiogenic shock.

Use of GLP-1 RAs is associated with a higher risk for ischemic optic neuropathy compared with SGLT2is and DPP4is.

Among populations surveyed, the odds of stroke were lower among foreign-born individuals and the lowest odds of stroke were seen among those who had recently immigrated. HealthDay News — Individuals ...

Recent wildfires contribute to a significant reduction in air quality across the Midwestern and Northeastern parts of Canada and the US.

Challenging patient interactions can be an adverse influence on the emotions and stress level of emergency physicians.

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

In response to a rising multistate outbreak of Cyclospora infections, the CDC has issued a health advisory for clinicians.

Higher levels of daytime light exposure are associated with a lower risk for dementia, while no association was seen for nighttime light.